Dementia vs Alzheimer’s

Dementia, a term for memory decline and other cognitive impairments severe enough to impede daily life, is most frequently caused by Alzheimer’s disease. Depressive disorders and Alzheimer’s dementia are related to the accumulation of toxic proteins within and surrounding brain cells. These proteins, known as amyloid and tau, build plaques and tangles that sever brain cells’ connections. Additionally, there is a reduction in the production of critical brain chemicals including the neurotransmitter acetylcholine.

Together, these factors cause both cell death and loss of function in the brain, first in regions of the brain in charge of memory and later in regions in charge of language, reasoning, and social behavior. All parts of the brain eventually experience damage. Alzheimer’s dementia or depression, which was initially characterized by Alois Alzheimer around 1906, is what causes Alzheimer’s dementia. The most prevalent type of dementia, considered to account for more than 50% of cases, is Alzheimer’s disease. Alzheimer’s dementia is a form of progressive dementia, meaning that symptoms get worse over time.

Dementia vs Alzheimer’s: Understanding the Differences

Dementia vs Alzheimer’s disease are two terms often used interchangeably, but they are not the same. While they both involve cognitive decline and memory problems, it’s essential to recognize the distinctions between these two conditions. In this post, we will discuss the differences between dementia vs Alzheimer’s disease to enhance our understanding of these complex neurological disorders.

Dementia:

• Dementia is a broad term encompassing a range of cognitive impairments.
• It is characterized by a decline in cognitive function, affecting memory, reasoning, communication, and daily life activities.
• Dementia is not a disease in itself but rather a syndrome resulting from various underlying causes.
• Causes of dementia include Alzheimer’s disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and more.
• Treatment options for dementia depend on the specific cause and may involve medication, therapy, and lifestyle changes.

Alzheimer’s Disease:

• Alzheimer’s disease is the most common cause of dementia, accounting for the majority of cases.
• It is a progressive neurodegenerative disease characterized by the accumulation of abnormal protein deposits in the brain, such as beta-amyloid plaques and tau tangles.
• Alzheimer’s primarily affects memory and cognitive functions.
• The exact cause of Alzheimer’s is still under investigation, but it likely involves a combination of genetic, environmental, and lifestyle factors.
• Alzheimer’s symptoms worsen over time, leading to significant disability and dependency in affected individuals.

Key Differences:

The key differences between dementia vs Alzheimer’s are as follows:

• Dementia is a general term for cognitive decline, while Alzheimer’s is a specific subtype of dementia.
• Alzheimer’s disease has distinctive pathological features, including the presence of beta-amyloid plaques and tau tangles.
• Other forms of dementia have different underlying causes and may require specific treatments.
• Accurate diagnosis is crucial, as it helps determine the appropriate management and care strategies for individuals affected by these conditions.

In summary, dementia is the overarching term for cognitive decline, while Alzheimer’s disease is a specific and prevalent type of dementia. Distinguishing between the two is vital for proper diagnosis and treatment. Whether it’s dementia vs Alzheimer’s, early detection and appropriate care can significantly improve the quality of life for individuals and their families facing these challenging conditions.

Alzheimer’s Dementia

Background

Alzheimer’s dementia or depression is a degenerative illness that starts with mild cognitive decline and may eventually impair one’s capacity to converse and react to their surroundings. The brain regions that are responsible for thought, recall, and language are affected by Alzheimer’s disease. It can significantly impair a person’s capacity to perform day-to-day tasks.

Description

The cortex of the brain and several subcortical regions lose neurons and synapses as a result of Alzheimer’s disease. Gross shrinkage of the impacted regions is the outcome of this loss, including atrophy in the temporal and parietal lobes, as well as portions of the frontal lobe of the brain as well as cingulate gyrus. Additionally, there is degeneration in the brainstem nuclei, especially in the locus coeruleus located in the pons. When compared to identical images from normal older persons, studies employing MRI and PET have shown that certain parts of the brain in patients with Alzheimer’s dementia and depression shrink as the disease advances from mild cognitive dysfunction to Alzheimer’s disease.

By microscopy, neurofibrillary tangles and ‘A’ plaques, particularly in the hippocampus, are discernible in Alzheimer’s disease patients’ brains. However, Alzheimer’s disease can develop in the neocortex even in the absence of neurofibrillary tangles. The beta-amyloid peptide as well as cellular debris build up in dense, largely insoluble plaques outside and surrounding neurons. As the microtubule-associated molecule tau becomes hyperphosphorylated, tangles (also known as neurofibrillary tangles) form in the cells themselves. As a result of aging, plaques and tangles appear in the brains of many older people, but those with Alzheimer’s dementia or depression have more of them in some areas of the brain, such as the temporal lobe. Alzheimer’s patients frequently have Lewy bodies in their brains.

Sign and Symptoms

Short-term cognitive impairment, feeling disoriented and losing things are early indicators of Alzheimer’s dementia or depression. Complex tasks can be difficult for people with Alzheimer’s dementia to complete at first, and they may struggle to organize and communicate their thoughts. However, it should be kept in mind that several of the alterations in mood and behavior may not be caused by the condition but rather may be related to communication issues, as well as being normal reactions to trying circumstances, oppressive structures, a lack of adequate support, and unhelpful attitudes.

The symptoms of Alzheimer’s dementia worsen over time and might become increasingly disruptive to daily living. More severe memory loss and communication and language problems appear. Confusion, personality and mood changes, as well as challenges with daily routines like dressing and washing, may all occur. Additionally, those with advanced Alzheimer’s dementia frequently struggle with walking, sitting, and finally swallowing. Alzheimer’s dementia is a fatal disorder, albeit each person’s rate of progression is unique.

Prevalence and Incidence

Numerous Americans live with Alzheimer’s disease or another form of dementia. The proportion and number of Americans experiencing Alzheimer’s dementia will rise together with the expansion of the US population 65 and older. In 2022, there will be 6.5 million Americans 65 and older who have Alzheimer’s. 73% of people are 75 years of age or older. Alzheimer’s affects 1 in 9 people aged 65 and older (10.7%). That’s because being older makes you more likely to develop dementia. By 2050, there are expected to be 88 million Americans aged 65 and older, up from 58 million people in 2021. As the age range with the highest risk of Alzheimer’s disease approaches, the baby-boom era (Americans between the years 1946 to 1964) has indeed started to reach that point. In reality, the oldest individuals of the baby-boom generation will be 75 in 2021. Alzheimer’s is most common among elderly.

The incidence of Alzheimer’s, or how many people per 100,000 are diagnosed with the disease for the first time each year, appears to be declining. This trend has been attributed to reductions in risk factors for Alzheimer’s disease over the 20th century, like high blood pressure and illiteracy. However, despite this reduced incidence rate, it is anticipated that the number of persons with Alzheimer’s will continue to rise due to a growth in the population of adults 65 and older, who are at an elevated risk of developing the disease. How COVID-19, including infection, works is unknown. The COVID-19 (the virus responsible for it) pandemic’s effects on healthcare access and mortality rates also had an impact on the prevalence and ratios of Alzheimer’s patients in the US.

Surveillance and Monitoring

Questionnaires, interviews with patients and caregivers, and less frequently direct clinic testing or observation, are the traditional methods used to measure cognitive and functional deterioration. These evaluations are often based on (caregiver) recall and only conducted periodically, therefore they reflect a frequently biased picture of the patient’s function as it was observed in a clinical setting. Remote monitoring technologies (RMTs), such as wearables like activity trackers, smartphone apps, and fixed sensors in the house, are non-intrusive and can assess parameters objectively and continually. Since RMTs may evaluate processes in a “real-world” setting, they are appropriate for monitoring Alzheimer’s dementia because they have the potential to offer more reliability and sensitivity than traditional in-clinic evaluations of function.

Epidemiological Investigation

The ‘What’

Alzheimer’s is brought on by the loss of neurons, and as the condition worsens, the brain gets smaller. As Alzheimer’s disease worsens over time, people have more distressing and obvious symptoms. On average, individuals with this disease survive up to eight years after being diagnosed. Although there is a lot more research being done on Alzheimer’s therapy and prevention, there is unfortunately no cure or effective treatment for the disease.

The ‘Who’

There are probably multiple causes, each of which can have a different impact on an individual. The most prevalent risk factor for Alzheimer’s disease is aging. Family history: Genetics may be involved in the onset of Alzheimer’s disease, according to researchers. Genes do not, however, determine fate. One’s risk of getting Alzheimer’s disease may be lowered by leading a healthy lifestyle.

Two significant, lengthy studies suggest that appropriate physical activity, a healthy diet, moderate alcohol use, and quitting smoking may be beneficial for people. One can pay heed to brief audio to learn details about the study. Years before any symptoms start to show, the brain can start to change. Researchers are looking into the potential influences of environment, diet, and education on the onset of Alzheimer’s disease. There is mounting proof that healthy habits, which have been linked to lower risks for heart disease, diabetes, and cancer, may also lower the chance of subjective cognitive loss.

The ‘Where’

It’s crucial to visit a primary care physician frequently since they might spot changes that indicate a patient needs to be tested. Most primary care physicians are capable of handling the diagnostic procedure. They may suggest that patients seek diagnosis and treatment from a professional, like a neurologist.

The ‘When’

Alzheimer’s disease has quite differentiated signs. One should seek professional help if they experience cognitive impairment that interferes with daily tasks. Caregivers should be alert for these indicators in a family member or friend because it might be challenging to recognize or comprehend these alterations and to seek immediate aid.

The ‘Why’

It’s crucial to find Alzheimer’s early. It is important to get checked out as soon as possible if someone starts to exhibit any of the symptoms. Even though there is no treatment for this illness, an accurate diagnosis could open doors to cutting-edge therapies and clinical studies, help patients maintain their independence for longer, and aid in better planning for long-term care.

Screening

PET, MRI, or CT scans are frequently used in structural imaging as part of a standard medical evaluation for Alzheimer’s disease. These examinations are largely performed to exclude other illnesses that might present with similar symptoms. A unique substance that can be infused into the blood and binds to amyloid protein clumps in the brain was created by scientists. A PET scanner can pick up the tiny radioactive signal that the substance generates.

Table: Attributes of PET scan for screening of Alzheimer’s dementia

	Sensitivity	Specificity	Predictive value	Cost
PET scan	78% (95% CI)	81% (95% CI)	85%	Can cost $5,000 to $7,000 (not covered by insurance).

Plan

Currently, family members care for a large number of Alzheimer’s patients at home. Both the caregiver and the person receiving care can benefit from providing care. It may result in the caregiver experiencing personal fulfillment, such as joy from supporting a friend or family member, the acquisition of new skills, and strengthening family ties.

By looking for symptoms during the medical admission assessment, nurses play a critical role in identifying dementia among older patients being treated in hospitals. The goal of dementia interventions is to prolong patient independence and function as much as feasible. The patient’s safety, mobility in self-care tasks are all key objectives as well.

Primary Intervention

The very first three of the key periods indicated above—i.e., before the development of early degenerative changes, after the transitions but before symptoms appear, or in early symptomatic disease—offer the best chances for primary intervention and the management of the patient’s quality of life. The primary goal of prevention is to stop or lessen the progression of Alzheimer’s neuropathology. Therefore, knowledge of the disease’s genesis or, at the very least, its risk factors, is necessary.

Secondary Intervention

The early discovery, treatment, and/or management of the illness constitute secondary prevention. Although it has been hypothesized that neural tissue transplantation may help change the pathogenesis of Alzheimer’s dementia, this looks to be a doubtful management option in the short term. This is typically attempted by medication. There are two major groups of current treatments for Alzheimer’s dementia symptoms.

The use of cholinesterase inhibitors to treat the mild-to-moderate symptoms of Alzheimer’s dementia includes donepezil, rivastigmine, and galantamine. They work by attaching to the enzyme acetylcholinesterase, which usually degrades the neurotransmitter acetylcholine. As a result, a greater amount of acetylcholine is accessible to operate on brain cells, improving neurotransmission and lowering Alzheimer’s dementia symptoms associated with memory.

Memantine and other NMDA receptor antagonists have been licensed for the treatment of moderate-to-severe Alzheimer’s dementia symptoms. Although they have multiple mechanisms of action, the primary one is believed to involve blocking electrical activity passing through NMDA receptors located on the exterior of brain cells. This helps alleviate some of the behavioral and cognitive manifestations of Alzheimer’s dementia by lowering aberrant brain cellular functions, which can harm brain cells.

Tertiary Intervention

Once symptoms have appeared, the goal of tertiary prevention techniques is to reduce patients’ excessive disability. One method is to establish programs like memory training, the use of memory aids, guidance on how to organize daily routines, and reality orientation initiatives to make up for the cognitive deficiencies of Alzheimer’s dementia patients.

Conclusion

A degenerative neurologic condition called Alzheimer’s disease results in the death of brain cells and brain shrinkage. The most frequent cause of dementia is Alzheimer’s disease. Symptoms may momentarily get better or progress more slowly with medication. These therapies occasionally enable persons with Alzheimer’s disease to maintain independence and optimize function. Numerous services and programs are available to assist those who have Alzheimer’s disease and those who care for them.

References

Abeysinghe, A. A. D. T., Deshapriya, R. D. U. S., & Udawatte, C. (2020). Alzheimer’s disease; a review of the pathophysiological basis and therapeutic interventions. Life sciences, 256, 117996.

De Roeck, E. E., De Deyn, P. P., Dierckx, E., & Engelborghs, S. (2019). Brief cognitive screening instruments for early detection of Alzheimer’s disease: a systematic review. Alzheimer’s research & therapy, 11(1), 1-14.

Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., … & van der Flier, W. M. (2022). Global estimates on the number of persons across the Alzheimer’s disease continuum. Alzheimer’s & Dementia.

Hampel, H., Mesulam, M. M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., … & Khachaturian, Z. S. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain, 141(7), 1917-1933.

James, B. D., & Bennett, D. A. (2019). Causes and patterns of dementia: an update in the era of redefining Alzheimer’s disease. Annual review of public health, 40, 65-84.